William Hagstrom

Jun 15, 2016

Genalyte has appointed William Hagstrom to its board of directors. Hagstrom has more than three decades of executive and board-level experience in the healthcare and diagnostic sectors, including founding Octave Bioscience, where he currently serves as CEO. He also previously served as president and CEO of Crescendo Bioscience, and as president of Alpha BioPartners.

More Like This

Jul 20, 2018

Jerry Williamson

NanoView Biosciences has appointed Jerry Williamson as CEO. Williamson succeeds David Freeman, who will remain with the firm as chief operating officer. Williamson has 30 years of experience in commercial operations, business development, and corporate management in the life science industry. He previously served as president and CEO of KEW, and as CEO and president of Metamark Genetics.

Jul 18, 2018

Feng Deng

Quantapore has announced that Feng Deng has joined the firm's board of directors in connection with the its latest financing round. Deng is the founder of Northern Light Venture Capital.

Jul 17, 2018

Laurence Klotz

MiR Scientific (formerly miR Diagnostics) has appointed Laurence Klotz as chief medical officer. Klotz currently serves as chairman of the World Urologic Oncology Federation. He has also been a member of the Institute of Medical Science and a graduate faculty member at the University of Toronto since 2005, as well as a professor of surgery at the University of Toronto since 2000.

Jul 13, 2018

David Karow

Human Longevity announced that its board has appointed David Karow interim CEO. Karow previously served as HLI's chief of radiogenomics. Prior to HLI, Karow spent twenty years in research, clinical practice, and training at the University of California, San Diego, the University of California, Los Angeles, and the University of Michigan.

Jul 13, 2018

Leena Das-Young

Guardant Health has appointed Leena Das-Young to serve as general manager of its LUNAR program. In her new role, Das-Young will oversee all work applying Guardant Health's technology and database of more than 70,000 clinical Guardant360 assay results, toward new applications in early-stage cancer, such as residual detection, recurrence monitoring, and early detection.

Prior to joining Guardant, Das-Young was vice president and head of the late phase strategy development group at Pfizer's oncology group, where she was responsible for a portfolio of oncology programs including Ibrance, Xalkori, Besponsa, Sutent, lorlatinib, and others. Prior to her roles in product development, she served in various commercial roles responsible for several successful launches at both Pfizer and Bayer.  She holds BS and Doctor of Pharmacy degrees from Purdue University.

Jul 13, 2018

Jinjie Hu

Laboratory for Advanced Medicine announced today that it has appointed Jinjie Hu as the firm's Chief Regulatory Officer. Hu currently serves as President and principal consultant at Axteria BioMed Consulting, and as senior consultant for Biologics Consulting Group. Hu has also served as World Health Organization advisor for its diagnostic pre-qualification program, as well as the International Network Committee chair of the FDA alumni association. 

Jul 13, 2018

David Byram

GeneNews announced that it has appointed David Byram as Chief Commercial Officer for its US lab, Innovative Diagnostics Laboratory (IDL). Byram will oversee all of the IDL customer's-facing activities, including sales, client relations, and commercial operations. Prior to joining IDL, Byram was VP, commercial and government affairs for Braeburn Pharmaceuticals. Prior to Braeburn, Byram held positions as senior VP, commercial affairs for Orexo AB/US, US director, public sector for Indivior, and senior director, strategic accounts and public affairs for Janssen Biotech. 

Jul 12, 2018

Johnson Chiang, Rixun Fang

Johnson Chiang has been appointed chief technology officer and Rixun Fang director of assay development at Alveo Technologies.

Chiang was previously head of systems integration and molecular biology at Foundation Medicine. He also held senior management positions at Life Technologies and at Thermo Fisher Scientific. Prior to that, he led molecular diagnostic product development projects at Applied MEMS, Applied Biosystems, and Cepheid.

Fang previously led several molecular biology research and IVD development projects at Applied Biosystems, Life Technologies, and Thermo Fisher Scientific.

Jul 12, 2018

Freenome Impact Advisory Board

Freenome has announced the creation of what it calls its Impact Advisory Board, a group tasked with helping the company optimize strategies, including those that will guide its first commercial launch of a blood-based, artificial intelligence-derived genomic test for the early detection of colorectal cancer.

The new board includes NDA Partners' Alberto Gutierrez, a former 25-year veteran of the US Food and Drug Administration, who will be tasked with guiding regulatory strategy. Joining Gutierrez are two experts on payor strategy: Louis Jacques, chief clinical officer of ADVI Health and former head of the Centers for Medicare and Medicaid Services' Coverage and Analysis Group; and Sherie Smalley, senior medical director of medical policy at UPMC Health Plan.

It also includes clinical development advisors with expertise in gastroenterology, including Douglas Robertson from the US Multi-Society Task Force of Colorectal Cancer.

Jul 10, 2018

Michael Sussman, Christopher Bradfield

Michael Sussman will become director of the Genome Center of Wisconsin, which is located within the University of Wisconsin-Madison Biotechnology. To assume his new role, he is stepping down as director of the Biotechnology Center. Christopher Bradfield, a professor of oncology at UW-Madison, has been named interim director of the Biotechnology Center.

Jul 10, 2018

Christopher Benoit

Christopher Benoit has been appointed as CEO of TwinStrand Biosciences after joining the company's board of directors earlier this year. Previously, he held various roles at Enzymatics, a company he co-founded. Qiagen acquired Enzymatis in 2014. He is also a member of the board of TangenDX, a point-of-care molecular diagnostics company.

Jul 10, 2018

Fayyaz Memon

Immunexpress has appointed Fayyaz Memon as the firm's VP of regulatory affairs and quality. With over 25 years of experience in the life science industry, Memon has previously served in leadership positions at Asuragen, Qiagen, PrimeraDx, Thermo Fisher Scientific, Digene, SmithKline Beecham, and Johnson & Johnson.

Jul 10, 2018

Violaine Mélen, Stéphane Cruveiller

PathoQuest has appointed Violaine Mélen as its head of quality assurance and regulatory affairs. In the new position, Mélen will oversee the maintenance of product quality and compliance in line with the firm's quality management system, while also leading the firm's regulatory strategies. She has more than 12 years of experience in regulatory affairs, quality assurance, and clinical affairs within the biotech and pharmaceutical industries. Mélen previously worked at Bio-Rad Laboratories where she was responsible for implementing risk management procedures with a specific focus on infectious disease.

In addition, PathoQuest has appointed Stéphane Cruveiller as its chief technology information officer. As CTIO, Cruveiller will be responsible for the technical aspects of the firm's bioinformatics pipeline and alignment information technology-related development initiatives with its business goals. Cruveiller previously served as team leader at the François Jacob Institute of Biology - Genoscope of the French Alternative Energies and Atomic Energy Commission at the Laboratory of Bioinformatics Analyses for Genomics and Metabolism.

Jul 09, 2018

George Golumbeski, Onaiza Cadoret-Manier, Fred Kohler, Angela Lai

Grail has added to its executive team, hiring George Golumbeski as president, Onaiza Cadoret-Manier as chief commercial officer, and Fred Kohler as vice president of people. The firm has also promoted Angela Lai to chief technology officer.

Golumbeski most recently served as executive vice president of business development for Celgene, and currently serves on the boards of several biotechnology companies, including KSQ Therapeutics, Carrick Therapeutics, Enanta Pharmaceuticals, and MorphoSys. He will replace Ken Drazan as president, who has stepped down to work on helping early-stage start-up firms secure funding. Drazan will continue to serve as an advisor to Grail. Golumbeski will also join Grail's board of directors.

Cadoret-Manier joins Grail from Genentech where she was vice president of the respiratory franchise. Previously, she held various senior management positions overseeing sales and marketing for several products at Genentech, Pfizer, Amylin Pharmaceuticals, and Quest Diagnostics.

Kohler has joined Grail from Roche, where he most recently led transformation work. Kohler previously worked at Autodesk and Juniper Networks, where he held a variety of human resources roles.

Lai has served as vice president of clinical technology at Grail since July 2016. She was responsible for building Grail's software systems team and supporting the company's clinical studies.

Jul 06, 2018

Lyn Rees, Stephen Little, Keng Hsu

Lyn Rees has become CEO of Premaitha Health, replacing Stephen Little, who is now the company's executive vice chairman. Rees joins Premaitha from BBI Group, where he was most recently CEO.

In addition, Keng Hsu has become Premaitha's chief operating officer for Asia. He used to be CFO of Yourgene Bioscience, which Premaitha acquired last year.

Furthermore, Alan Chang has stepped down as non-executive director of Premaitha to focus on other business interests.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.